Mainz Biomed N.V. (MYNZ)
Market: NASD |
Currency: USD
Address: Robert Koch Strasse 50
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product. The company was founded in 2008 and is based in Mainz, Germany.
📈 Mainz Biomed N.V. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$14.00
-
Upside/Downside from Analyst Target:
815.03%
-
Broker Call:
2
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
<0%
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Mainz Biomed N.V.
| Date | Reported EPS |
|---|
| 2025-04-06 | - |
| 2025-04-01 | - |
| 2025-03-31 | - |
| 2024-12-18 | - |
| 2024-04-09 | -0.24 |
| 2024-04-08 | -0.24 |
| 2023-11-16 | -0.39 |
| 2023-11-15 | -0.39 |
| 2023-08-15 | -0.56 |
| 2023-08-14 | -0.56 |
| 2023-04-27 | -0.45 |
| 2023-04-26 | -0.45 |
| 2023-04-07 | - |
| 2023-04-06 | - |
| 2022-11-02 | - |
| 2022-11-01 | - |
| 2022-09-07 | - |
| 2022-09-06 | - |
| 2022-05-02 | - |
| 2022-05-01 | - |
| 2022-01-28 | - |
| 2022-01-27 | - |
📰 Related News & Research
No related articles found for "mainz biomed".
